Brent Saunders exits Bausch + Lomb just as earnings improve. What changes under Thomas Appio?
Bausch + Lomb names Thomas Appio interim CEO as both companies expect higher 2026 EBITDA guidance. October 28 results will test momentum.
Pharma & Biotech
Medical Devices & Diagnostics
Why Bausch + Lomb’s ASCRS 2026 data slate matters for premium IOL competition and dry eye care
Find out why Bausch + Lomb’s ASCRS 2026 data package could reshape competition in cataract surgery, dry eye care, and ophthalmology platforms.